Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,146 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations
  • Hospital de Pediatría S.A.M.I.C. "Juan P. Garrahan" Buenos Aires, Argentina
  • Australian and New Zealand Children's Haematology/Oncology Group Clayton, Victoria, Australia
  • North Adelaide- Womens and Childrens Hospital Adelaide, Australia
  • Monash Children's Hosptial Clayton, Australia
View all 124 locations
View Trial Details
Recruiting

CAR-T Cell Therapy for ALL

NCT07695012

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +13 more
Locations
  • National University of Medical Sciences, Clinical Trial Unit Rawalpindi, Pakistan
View Trial Details
Recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

NCT05077527

Conditions
AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, Blood-Borne Infections, +36 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of Illinois at Chicago Chicago, Illinois, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Montefiore Medical Center - Moses Campus The Bronx, New York, United States
View Trial Details
Recruiting

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

NCT06508983

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing Municipality, China
  • Guangzhou First People's Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • First Affiliated Hospital of Henan University of Science and Technology Luoyang, Henan, China
View Trial Details
Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06015880

Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Hemic and Lymphatic Diseases, High Grade B-Cell Lymphoma, +11 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Northwestern University Chicago, Illinois, United States
View Trial Details
Recruiting

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

NCT04685616

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • Stanford University - (Stanford Cancer Institute) Stanford, California, United States
  • University of Miami School of Medicine Miami, Florida, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Royal North Shore Hospital Saint Leonards, New South Wales, Australia
View all 72 locations
View Trial Details

Related conditions